BIOMAT Database Logo BIOMAT Database Logo

Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice. 2001

B Hemmeryckx, and A van Wijk, and A Reichert, and V Kaartinen, and R de Jong, and P K Pattengale, and I Gonzalez-Gomez, and J Groffen, and N Heisterkamp
Department of Hematology/Oncology, Childrens Hospital Los Angeles Research Institute and the Keck School of Medicine of the University of Southern California, 90027, USA.

The adapter protein Crkl has been implicated in the abnormal signal transduction pathways activated by the Bcr/Abl oncoprotein, which causes Philadelphia-positive leukemias in humans. To investigate the role of Crkl in tumorigenesis, we have generated transgenic mice that express human Crkl from the CRKL promoter. Western blot analysis showed a 4-6-fold overexpression of transgenic Crkl above endogenous crkl in two lines and increased constitutive complex formation between Crkl and C3G, an exchange factor for the small GTPase Rap1. This was associated with a significant increase in integrin-based motility of transgenic macrophages. Overexpression of Crkl was associated with increased incidence of tumor formation, and Rap1 was activated in a metastatic mammary carcinoma. The coexpression of Crkl and Bcr/Abl in mice transgenic for P190 BCR/ABL and CRKL markedly increased the rapidity of development of leukemia/lymphoma, decreasing the average survival by 3.8 months. These results provide direct evidence that Crkl plays a role in tumor development and is important in the leukemogenesis caused by Bcr/Abl.

UI MeSH Term Description Entries
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008297 Male Males
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D009687 Nuclear Proteins Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus. Nucleolar Protein,Nucleolar Proteins,Nuclear Protein,Protein, Nuclear,Protein, Nucleolar,Proteins, Nuclear,Proteins, Nucleolar
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011401 Promoter Regions, Genetic DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes. rRNA Promoter,Early Promoters, Genetic,Late Promoters, Genetic,Middle Promoters, Genetic,Promoter Regions,Promoter, Genetic,Promotor Regions,Promotor, Genetic,Pseudopromoter, Genetic,Early Promoter, Genetic,Genetic Late Promoter,Genetic Middle Promoters,Genetic Promoter,Genetic Promoter Region,Genetic Promoter Regions,Genetic Promoters,Genetic Promotor,Genetic Promotors,Genetic Pseudopromoter,Genetic Pseudopromoters,Late Promoter, Genetic,Middle Promoter, Genetic,Promoter Region,Promoter Region, Genetic,Promoter, Genetic Early,Promoter, rRNA,Promoters, Genetic,Promoters, Genetic Middle,Promoters, rRNA,Promotor Region,Promotors, Genetic,Pseudopromoters, Genetic,Region, Genetic Promoter,Region, Promoter,Region, Promotor,Regions, Genetic Promoter,Regions, Promoter,Regions, Promotor,rRNA Promoters
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

B Hemmeryckx, and A van Wijk, and A Reichert, and V Kaartinen, and R de Jong, and P K Pattengale, and I Gonzalez-Gomez, and J Groffen, and N Heisterkamp
BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
May 2002, Oncogene,
B Hemmeryckx, and A van Wijk, and A Reichert, and V Kaartinen, and R de Jong, and P K Pattengale, and I Gonzalez-Gomez, and J Groffen, and N Heisterkamp
Restricted oncogenicity of BCR/ABL p190 in transgenic mice.
August 1992, Cancer research,
B Hemmeryckx, and A van Wijk, and A Reichert, and V Kaartinen, and R de Jong, and P K Pattengale, and I Gonzalez-Gomez, and J Groffen, and N Heisterkamp
IFN-alpha treatment of p190 bcr abl transgenic mice.
July 1994, International journal of oncology,
B Hemmeryckx, and A van Wijk, and A Reichert, and V Kaartinen, and R de Jong, and P K Pattengale, and I Gonzalez-Gomez, and J Groffen, and N Heisterkamp
BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.
December 1995, Blood,
B Hemmeryckx, and A van Wijk, and A Reichert, and V Kaartinen, and R de Jong, and P K Pattengale, and I Gonzalez-Gomez, and J Groffen, and N Heisterkamp
Clonal characteristics of acute lymphoblastic cells derived from BCR/ABL p190 transgenic mice.
July 1992, Oncogene,
B Hemmeryckx, and A van Wijk, and A Reichert, and V Kaartinen, and R de Jong, and P K Pattengale, and I Gonzalez-Gomez, and J Groffen, and N Heisterkamp
Bcr/Abl associated leukemogenesis in bcr null mutant mice.
April 1998, Oncogene,
B Hemmeryckx, and A van Wijk, and A Reichert, and V Kaartinen, and R de Jong, and P K Pattengale, and I Gonzalez-Gomez, and J Groffen, and N Heisterkamp
Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival.
July 2012, Blood,
B Hemmeryckx, and A van Wijk, and A Reichert, and V Kaartinen, and R de Jong, and P K Pattengale, and I Gonzalez-Gomez, and J Groffen, and N Heisterkamp
Clonal development and karyotype evolution during leukemogenesis of BCR/ABL transgenic mice.
February 1992, Blood,
B Hemmeryckx, and A van Wijk, and A Reichert, and V Kaartinen, and R de Jong, and P K Pattengale, and I Gonzalez-Gomez, and J Groffen, and N Heisterkamp
CRKL binding to BCR-ABL and BCR-ABL transformation.
March 1999, Leukemia & lymphoma,
B Hemmeryckx, and A van Wijk, and A Reichert, and V Kaartinen, and R de Jong, and P K Pattengale, and I Gonzalez-Gomez, and J Groffen, and N Heisterkamp
The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice.
November 2002, Leukemia research,
Copied contents to your clipboard!